Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Pixelworks
Pixelworks completed a definitive pivot from hardware manufacturing to a pure-play technology licensing model. The company sold its Shanghai semiconductor subsidiary, cleared its balance sheet of lega...
- Completed sale of Shanghai semiconductor subsidiary, resulting in a clean balance sheet with $58 million in cash and zero debt.
- Executed a strategic pivot to a pure-play technology licensing business, shedding hardware manufacturing operations.
- Q1 2026 revenue was approximately $450,000, derived entirely from TrueCut Motion platform and motion grading services.
- +9 more takeaways
CuriosityStream Q1 2026 Earnings Call - Deliberate Q1 Trade-Off Sets Stage for AI Licensing Growth
CuriosityStream reported $15.2 million in Q1 2026 revenue, a modest year-over-year increase, but management framed the quarter as a strategic pivot rather than a setback. The company deliberately prio...
- Q1 2026 revenue reached $15.2 million, up slightly from $15.1 million in Q1 2025, with subscription revenue at $8.8 million and licensing at $6 million, an 11% year-over-year increase.
- Management deliberately prioritized structuring broader AI licensing partnerships over near-term revenue recognition, resulting in lumpy AI licensing income but positioning for larger, more durable deals.
- Full-year 2026 revenue guidance raised to $75-$80 million, with first-half guidance of $35-$41 million, reflecting confidence in licensing becoming the primary growth engine.
- +7 more takeaways
SoundThinking (SNDK) Q1 2026 Earnings Call - Cleveland Renewal Validates Platform Moat as SafePointe Invests Ahead of Healthcare Mandates
SoundThinking reported Q1 2026 revenue of $24.2 million, in line with consensus, but adjusted EBITDA dipped to roughly breakeven due to the structural cost-heavy nature of the first quarter and contin...
- Q1 revenue came in at $24.2 million, exactly in line with consensus, while adjusted EBITDA landed near breakeven at approximately negative $100,000, reflecting the structural cost concentration of Q1 and continued SafePointe investments.
- Full-year guidance remains intact: $109–$111 million in revenue (5%–7% YoY growth) and 16%–18% adjusted EBITDA margin, with management attributing Q1 weakness to predictable annual cost front-loading and back-loaded revenue recognition.
- The Cleveland ShotSpotter renewal proceeded despite public competitive pressure, with city leadership citing an 80% homicide solve rate as justification, underscoring management’s thesis that operational performance and 25 years of acoustic data create a durable moat over newer entrants.
- +7 more takeaways
Intrusion Inc. Q1 2026 Earnings Call - Revenue Misses on DoD Delay, But New Texas Contract and PortNexus Partnership Signal Growth
Intrusion Inc. reported a sharp revenue decline in Q1 2026, driven by a delayed Department of Defense contract extension and broader government funding constraints. Total revenue fell 40% sequentially...
- Q1 2026 revenue fell to $0.9 million, down 40% sequentially and 50% year-over-year, primarily due to a delayed Department of Defense contract extension.
- Operating expenses increased 7% sequentially to $4.2 million, reflecting strategic investments in commercial sales, marketing, and brand initiatives.
- Net loss widened to $3.6 million, or $0.18 per share, compared to a $2.1 million loss in Q1 2025, driven by lower revenue and higher operating costs.
- +7 more takeaways
Celcuity Q1 2026 Earnings Call - Gedatolisib NDA PDUFA July 17, Subcutaneous Formulation Launched, Peak Revenue $2.5B
Celcuity’s Q1 2026 update centers on a single, high-stakes milestone: the FDA’s July 17 PDUFA decision for gedatolisib in HR-positive, HER2-negative advanced breast cancer. The company confirmed it re...
- FDA PDUFA for gedatolisib in wild-type HR+/HER2- breast cancer remains on track for July 17, 2026, with no regulatory red flags reported.
- Net loss widened to $52.8 million ($0.97/share) in Q1 2026, up from $37 million ($0.86/share) in Q1 2025, driven by commercial launch preparation.
- R&D expenses rose to $33.1 million (+11% YoY) due to higher employee/consulting costs and manufacturing, partially offset by lower VIKTORIA-1 trial costs.
- +9 more takeaways
BioStem Q1 2026 Earnings Call - Hospital Pivot and Margin Expansion on the Horizon
BioStem’s Q1 2026 results underscore a decisive pivot from a physician-office model to a hospital-focused strategy, driven by a January acquisition of BioTissue’s perinatal tissue allograft business. ...
- BioStem completed a transformative acquisition in late January, shifting its strategic focus from physician offices to the hospital channel, adding a diversified commercial infrastructure, GPO contracts, and a new portfolio of perinatal tissue allografts.
- First-quarter revenue totaled $6.1 million, with $5.4 million derived from hospital sales; this performance matches the acquired assets' run-rate over the 70 days BioStem owned them, validating the integration plan.
- The company retained the acquired sales team with minimal turnover and has nearly doubled its direct sales force to 35 representatives, with plans to reach 40 direct reps and expand its independent agent network by year-end.
- +7 more takeaways
Xos Holdings Inc Q1 2026 Earnings Call - Record Margins Driven by Hub and Powertrain Shift
Xos Holdings reported a record-breaking Q1 2026, delivering 95 units and generating $11.2 million in revenue, nearly double the prior year. The quarter was defined by a strategic pivot away from pure ...
- Revenue doubled year-over-year to $11.2 million, driven by a 227% increase in unit deliveries from 29 to 95 units.
- GAAP gross margins hit a company record of 38.6%, a significant improvement from 20.6% in Q1 2025 and a -50.5% loss in Q4 2025.
- Product mix shifted heavily toward higher-margin segments, with 63 powertrain systems sold to Blue Bird and approximately 22 Xos Hub units delivered.
- +7 more takeaways
Gambling.com Group Q1 2026 Earnings Call - SEO Decline Offset by Data Growth and AI-Driven Restructuring
Gambling.com Group reported flat Q1 revenue of EUR 40.4 million as a 13% surge in its sports data services business, fueled by OpticOdds enterprise growth and AI integrations with Claude and Perplexit...
- Q1 revenue of EUR 40.4 million was flat year-over-year, with sports data services growing 13% to EUR 11.2 million while marketing revenue declined 5% to EUR 29.2 million.
- OpticOdds enterprise growth drove the data segment, with international partners up 178% year-over-year and total active partners rising 24% quarter-over-quarter.
- AI integration is accelerating product stickiness, with OpticOdds now integrated into Claude and a new partnership with Perplexity expected to launch before the end of Q2.
- +7 more takeaways
Xanadu Q1 2026 Earnings Call - Photonics Quantum Leader Secures $302M Capital, Targets 500 Logical Qubits by 2030
Xanadu’s first quarterly earnings call as a public company on Nasdaq and the Toronto Stock Exchange revealed a firm in the scaling phase of photonic quantum computing. The company raised $302 million ...
- Xanadu completed its SPAC merger in March 2026, listing on Nasdaq and the Toronto Stock Exchange under the ticker XNDU, generating $302 million in gross proceeds.
- The company is in final negotiations for up to CAD 390 million in Canadian and Ontario government funding to support Project OPTIMISM and advanced semiconductor manufacturing.
- Q1 2026 revenue reached CAD 2.8 million, up from CAD 700,000 in the prior year quarter, primarily driven by DARPA QBI Stage B and government grant income.
- +9 more takeaways
Daré Bioscience Q1 2026 Earnings Call - First Product Revenue Expected in June as Ovaprene Shows Promise
Daré Bioscience is poised to record its first direct product revenue in June 2026 with the commercial launch of Flora Sync LF5, a vaginal probiotic suppository, followed by nationwide dispensing of it...
- Daré Bioscience expects to record its first direct product revenue in June 2026 with the launch of Flora Sync LF5, a vaginal probiotic suppository, marking a shift from a pure R&D company to one with commercial product revenue.
- Nationwide dispensing for DARE to PLAY, a topical sildenafil cream for women's sexual health, is targeted for summer 2026 via 503B compounding partner Bravado, following successful pre-fulfillment prescribing since February 2026.
- Ovaprene, a monthly intravaginal hormone-free contraceptive, received a second consecutive positive DSMB review in its Phase III trial, with a pregnancy rate of ~9% and improved tolerability, putting primary endpoint analysis within reach for 2027.
- +7 more takeaways